Literature DB >> 7853524

Distinct regions in human T-cell lymphotropic virus type I tax mediate interactions with activator protein CREB and basal transcription factors.

N Adya1, C Z Giam.   

Abstract

Human T-cell lymphotropic virus type I (HTLV-I) transactivator Tax augments transcription from three (cyclic AMP response element (CRE)-containing 21-bp repeats in the viral long terminal repeat and several other cis regulatory elements, including the NF-kappa B binding sites and the serum response element. Tax does not bind DNA directly; rather, it acts via cellular sequence-specific DNA binding proteins to stimulate transcription. We have shown recently that Tax forms multiprotein complexes with the heterodimeric and homodimeric forms of a ubiquitous cellular transcription factor, CREB (CRE binding protein). In vitro selection for preferred Tax-CREB binding sites indicates that the Tax-CREB complex exhibits greatly increased DNA recognition specificity and assembles preferentially on CRE motifs, TGACGT/C, flanked by long runs of G (5') and/or C (3') residues, as found in the HTLV-I 21-bp repeats. The indirect tethering of Tax to the 21-bp repeats via CREB is crucial for Tax transactivation. We now report the domain organization of Tax by characterizing its mutants. Tax mutants with alterations in the NH2 terminus, including three deletion mutants, Tax(6-353), Tax(21-353), and Tax(89-353), and two amino acid substitution mutants, M1 (H3S) and M7 (C29A, P30S), all failed to interact with CREB in vitro. In contrast, a short COOH-terminal deletion, Tax(1-319), and a Tax mutant with amino acid substitutions near the COOH end, M47 (L319R, L320S), were able to interact with CREB and the 21-bp repeats to assemble ternary Tax-CREB-DNA complexes. As demonstrated earlier, M1, M7, and M47 all failed to transactivate the HTLV-I long terminal repeat. Our data indicate that the defects in M1 and M7 result from an inability to interact with CREB. In contrast, the COOH-terminal mutations in M47 most likely inactivated the transactivation domain of Tax. As anticipated, a Tax mutant, M22 (G137A, L138S) which activated transcription from the 21-bp repeats with reduced capacity and was defective in trans activating the NF-kappa B binding sites, continued to interact with CREB in vitro, albeit with a lower level of efficiency. Finally, a glutathione S-transferase (GST)-Tax fusion protein with the GST moiety fused to the NH2 terminus of Tax failed to interact with CREB. Removal of the GST domain from GST-Tax by thrombin restores Tax's ability to assemble a ternary Tax-CREB-21-bp-repeat complex.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7853524      PMCID: PMC188794     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Isolation of an HTLV-1-like retrovirus from patients with tropical spastic paraparesis.

Authors:  S Jacobson; C S Raine; E S Mingioli; D E McFarlin
Journal:  Nature       Date:  1988-02-11       Impact factor: 49.962

2.  c-fos promoter trans-activation by the tax1 protein of human T-cell leukemia virus type I.

Authors:  M Fujii; P Sassone-Corsi; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

3.  In vitro mutagenesis of the human T-cell leukemia virus types I and II tax genes.

Authors:  A J Cann; J D Rosenblatt; W Wachsman; I S Chen
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

4.  A unique enhancer element for the trans activator (p40tax) of human T-cell leukemia virus type I that is distinct from cyclic AMP- and 12-O-tetradecanoylphorbol-13-acetate-responsive elements.

Authors:  J Fujisawa; M Toita; M Yoshida
Journal:  J Virol       Date:  1989-08       Impact factor: 5.103

5.  Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis.

Authors:  A Gessain; F Barin; J C Vernant; O Gout; L Maurs; A Calender; G de Thé
Journal:  Lancet       Date:  1985-08-24       Impact factor: 79.321

6.  Thymic atrophy characteristic in transgenic mice that harbor pX genes of human T-cell leukemia virus type I.

Authors:  Y Furuta; S Aizawa; Y Suda; Y Ikawa; H Kishimoto; Y Asano; T Tada; A Hikikoshi; M Yoshida; M Seiki
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

7.  The tat gene of human T-lymphotropic virus type 1 induces mesenchymal tumors in transgenic mice.

Authors:  M Nerenberg; S H Hinrichs; R K Reynolds; G Khoury; G Jay
Journal:  Science       Date:  1987-09-11       Impact factor: 47.728

8.  T-cell activation signals and human T-cell leukemia virus type I-encoded p40x protein activate the mouse granulocyte-macrophage colony-stimulating factor gene through a common DNA element.

Authors:  S Miyatake; M Seiki; M Yoshida; K Arai
Journal:  Mol Cell Biol       Date:  1988-12       Impact factor: 4.272

9.  Binding of host-cell factors to DNA sequences in the long terminal repeat of human T-cell leukemia virus type I: implications for viral gene expression.

Authors:  J K Nyborg; W S Dynan; I S Chen; W Wachsman
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

10.  Detection of human T-cell lymphoma/leukemia virus type I DNA and antigen in spinal fluid and blood of patients with chronic progressive myelopathy.

Authors:  S Bhagavati; G Ehrlich; R W Kula; S Kwok; J Sninsky; V Udani; B J Poiesz
Journal:  N Engl J Med       Date:  1988-05-05       Impact factor: 91.245

View more
  58 in total

1.  The oncoprotein Tax binds the SRC-1-interacting domain of CBP/p300 to mediate transcriptional activation.

Authors:  K E Scoggin; A Ulloa; J K Nyborg
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

2.  Human T-lymphotropic virus type 1 Tax protein complexes with P-TEFb and competes for Brd4 and 7SK snRNP/HEXIM1 binding.

Authors:  Won-Kyung Cho; Moon Kyoo Jang; Keven Huang; Cynthia A Pise-Masison; John N Brady
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

3.  Anchoring of CREB binding protein to the human T-cell leukemia virus type 1 promoter: a molecular mechanism of Tax transactivation.

Authors:  H A Giebler; J E Loring; K van Orden; M A Colgin; J E Garrus; K W Escudero; A Brauweiler; J K Nyborg
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

4.  Immortalization of T lymphocytes by human T-cell leukemia virus type 1 is independent of the tax-CBP/p300 interaction.

Authors:  M D Robek; L Ratner
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

5.  Tax abolishes histone H1 repression of p300 acetyltransferase activity at the human T-cell leukemia virus type 1 promoter.

Authors:  Kasey L Konesky; Jennifer K Nyborg; Paul J Laybourn
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

6.  An exposed KID-like domain in human T-cell lymphotropic virus type 1 Tax is responsible for the recruitment of coactivators CBP/p300.

Authors:  R Harrod; Y Tang; C Nicot; H S Lu; A Vassilev; Y Nakatani; C Z Giam
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

Review 7.  Epigenetics, drugs of abuse, and the retroviral promoter.

Authors:  Jasmine Shirazi; Sonia Shah; Divya Sagar; Michael R Nonnemacher; Brian Wigdahl; Zafar K Khan; Pooja Jain
Journal:  J Neuroimmune Pharmacol       Date:  2013-11-12       Impact factor: 4.147

8.  Complex formation between CREB and Tax enhances the binding affinity of CREB for the human T-cell leukemia virus type 1 21-base-pair repeats.

Authors:  M J Yin; R B Gaynor
Journal:  Mol Cell Biol       Date:  1996-06       Impact factor: 4.272

9.  The four and a half LIM family members are novel interactants of the human T-cell leukemia virus type 1 Tax oncoprotein.

Authors:  Áine McCabe; Kenichi Hashimoto; William W Hall; Noreen Sheehy
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

10.  XBP-1, a novel human T-lymphotropic virus type 1 (HTLV-1) tax binding protein, activates HTLV-1 basal and tax-activated transcription.

Authors:  Sebastian C Y Ku; Jialing Lee; Joanne Lau; Meera Gurumurthy; Raymond Ng; Siew Hui Lwa; Joseph Lee; Zachary Klase; Fatah Kashanchi; Sheng-Hao Chao
Journal:  J Virol       Date:  2008-02-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.